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C hronic hepatitis C virus (HCV) is a major medical and public health concern. Across the globe, approximately 170 million people are believed to be infected. (1) In the United States, the prevalence of HCV infection is approximately 2%, with 5-7 million Americans infected. (2) Chronic hepatitis C is a systemic infection that represents an important factor in morbidity and mortality. Hepatitis C is one of the most common causes of cirrhosis, a risk factor for hepatocellular carcinoma and an indicator for liver transplantation. Nonhepatic manifestations of HCV include insulin resistance, cryoglobulinemia, and renal disease. (3) HCV infection is also associated with substantial health care utilization, with an estimated direct cost of 6-7 billion USD annually in the United States alone. (4, 5) In addition, the cost of HCV extrahepatic manifestations has been estimated at 1.5 billion USD in 2014. (6) Overall costs associated with HCV may be even higher as current estimates do not include indirect costs of productivity. (4) The ultimate goal of public health is the eradication of diseases. Whereas eradication refers to the permanent infection incidence of zero throughout the world, elimination refers to an infection incidence of zero in a specific geographic area. (7) Despite recent advances in medicine, smallpox remains the only human disease that the World Health Organization (WHO) has confirmed to have been eradicated globally.
(8) Global efforts are currently underway for the eradication of other diseases, such as polio, malaria, yaws, and dracunculiasis.
(9) In the United States in particular, several notifiable diseases, such as polio and measles, have been reported to be eliminated, with vaccination playing an important role. (10) Criteria have been established to identify characteristics of diseases that are most likely to be candidates for eradication: technical feasibility, economic considerations, and social/political attention (Table 1) . (7) Technical feasibility can be further defined by the accuracy of diagnostic tests and the role humans play in the life cycle of the infectious agent. The costs of treatment combined with the lack of infrastructure in developing countries pose as barriers for the global eradication of HCV; however, HCV may be a potential candidate for elimination in the United States. Unlike other infections for which efforts to achieve eradication and elimination have revolved around immunization, the treatment of established HCV infection includes the use of direct-acting antiviral (DAA) agents. Our objective in this review is to ascertain the possibility of eliminating HCV using established public health qualifying criteria.
Methods

SEARCH STRATEGY
We used PubMed, GoogleScholar, and ScienceDirect databases to conduct our search using a combination of the following keywords: "hepatitis C virus", "eradication", "elimination", "prevention", "control", "economic burden", "vaccination", "direct antiviral agents", "interferon free", "treatment cost", "cost effectiveness analysis", "screening test sensitivity", "global epidemiology", "prevalence", "incidence", "transmission", "social and political support", "public awareness", "non-human reservoir", "syringe and needles", "correctional facilities", and "safe injection sites". Bibliographies of identified studies were searched for additional studies. We only considered studies published after 1975. We also used figures and statistics from the Centers of Disease Control and Prevention (CDC) and the National Institutes of Health.
Results and Discussion
TECHNICAL FEASIBILITY
Technical feasibility is one of the three cardinal pillars believed necessary for disease elimination ( Table 1) . The criteria for technical feasibility include: having no nonhuman reservoir of the disease, a sensitive diagnostic test, and an effective intervention to prevent the transmission of disease (Table 2) . Another criterion is having a strategy that has been tested in a geographic area and found to be effective (field-proven strategy). (7, 11) The following discussion will examine the technical feasibility of HCV using the above criteria. 
Nonhuman Reservoir
The absence of a nonhuman reservoir is a favorable feature for HCV elimination. When a pathogen cannot propagate outside a human host, it becomes more vulnerable to focused intervention and consequently cannot re-infect humans through cross-species transmission. (12) Without a nonhuman reservoir, interventions against smallpox, including mass vaccination, surveillance, and containment of infected individuals, were able to focus on human hosts and led to eradication of smallpox by 1980. (13, 14) In contrast, besides treating infected humans, the global malaria eradication campaign required use of insecticides against mosquito vectors, and the effort ultimately failed once those vectors developed resistance to the insecticides, leading to a resurgence of the disease in previously controlled areas. (12, 15) 
Practical and Sensitive Diagnostic Tools
Disease elimination requires highly sensitive and specific diagnostic tests for diagnosis and surveillance. The standard screening test for HCV is an enzymelinked immunosorbent assay that detects anti-HCV antibodies. The third generation of this screening test has been reported to have sensitivity and specificity up to 97% and 100%, respectively. (16) A positive antibody test is followed by HCV RNA testing by polymerase chain reaction that confirms an infection and quantifies the viral load. Both of these tests have been used widely for HCV diagnosis in many different health systems in developed countries. (17) Point-of-care HCV testing using fingerstick blood, such as OraQuick HCV Rapid Antibody Test (manufactured by OraSure Technologies, Bethlehem, Pennsylvania), is also available and has comparable sensitivity and specificity to that of the HCV enzyme-linked immunosorbent assay test. (18, 19) Such tests may be helpful in using limited resources to screen large groups of individuals. (20) While the diagnostic tests themselves are sensitive and specific, there is still room for improvement in using these tests to increase case identification and link patients to specialized care. For instance, historically less than 20% of patients diagnosed with HCV were referred to treatment. (21) To address this gap, University of California Los Angeles Health has implemented electronic health record HCV screening reminders and used a nonclinically trained patient care coordinator to facilitate both follow-up HCV RNA testing and linkage to care. After implementation of the program, HCV screening increased by 145%. (17) HCV antibody-positive patients who received HCV RNA testing also increased from 83% to 95% (P < 0.01), and the percentage of patients who attended their initial appointment with a specialist increased from 88% to 94%. The results of the study highlight the role of a coordinator to help bridge the gap from diagnosis to eventual potential treatment.
Bridging the gaps in our current HCV care cascade will also require clear targets to be successful. For human immunodeficiency virus (HIV) infection, the ambitious goal of 90% diagnosed, 90% on treatment, and 90% virally suppressed (90/90/90) has been proposed as a target that can potentially end the acquired immune deficiency syndrome (AIDS) epidemic by 2030, while no such goal has been proposed for HCV. (22) However, a mathematical model predicted that HCV will become a rare disease, defined as 1 in 1,500 persons, by 2036 when assuming 90% of highrisk individuals diagnosed, 80% accepted treatment, and 90% virally suppressed (90/80/90). (23, 24) This 90/ 80/90 goal can potentially be used as a target for HCV elimination, although further study is needed to assess its true utility on HCV incidence.
Surveillance
Disease elimination also requires a surveillance program to allow us to fully grasp the scope of the current HCV epidemic and to monitor our progress. HCV surveillance in the United States has been ongoing since 1982, but the program is chronically underfunded as only seven jurisdictions are funded by the CDC. (25, 26) Additionally, local health departments are responsible for reporting to the CDC, and the data aggregation across different levels of government is not always accurate. (26) HCV infection is also more prevalent among marginalized groups, such as the homeless, prisoners, and intravenous drug users (IVDU), who have little or no access to health care. As a result, estimating the true prevalence of HCV has been difficult. Using data reported on HCV prevalence among the aforementioned groups and the total population of each group, the most conservative estimation has put HCV prevalence in the United States at approximately 5.2 million cases, which is 1.5 million more than the prevalence reported by the National Health and Nutrition Examination Survey and the CDC. (2) The results of this study highlight the need for additional community outreach programs to administer screening tests among high-risk populations along with the employment of a dedicated database for HCV surveillance. (27) 
Effective Intervention Tools
There are a number of tools to prevent and treat HCV. Injectable drug use is one of the most common modes of transmission of HCV. Consequently, clean syringe and needle exchange programs (SNPs) have been demonstrated to reduce HCV transmission rates among injectable drug users. A number of cities have shown up to a 29% reduction in HCV prevalence among IVDU in over an almost 10-year period of time with needle exchange programs. (28) HCV incidence among IVDU fell by 10% to 25% in the 1980s after SNPs were introduced for HIV prevention. (27, 29) Unfortunately, widespread use of SNPs is limited by insufficient funding. Current laws that restrict the sale of needles and syringes in pharmacies may also contribute to the spread of bloodborne diseases. (30) Hepatitis C antibodies are not neutralizing, and therefore patients with a history of HCV remain at risk of re-infection after they clear the initial viral infection. Opioid substitution therapy (OST) and mental health services may decrease the likelihood of re-infection. In a population-based cohort study evaluating 5,915 patients with HCV, the overall reinfection rate in IVDU was 1.53 per 100 personyears. (31) However, in IVDU who achieved sustained viral response (SVR) for initial infection, the re-infection incidence decreased to 1.14 and was even lower (0.84) for those who received OST and mental health services. (31) Currently, many medical services are still reluctant to treat IVDU due to concerns over nonadherence and re-infection risk, but these data suggest that augmenting DAA treatment with OST and mental health services will prevent re-infection. (32) Prophylactic vaccination has played a crucial role in eliminating diseases (e.g., polio, smallpox, measles, and rubella), but such a vaccine is not yet available for HCV. There are multiple challenges toward developing a vaccine, including high mutation rates, epitope shielding, and innate immunity signaling blockades. (33) Although the lack of a nonhuman reservoir is a favorable feature for elimination, this feature also prevents the use of suitable small animal models for vaccine candidate evaluation. (33) Three vaccines are currently in clinical trials; a few others have completed their phase 1 clinical trial without published results, according to www.clinicaltrials.gov. (34) Over the past several years, there has been a paradigm shift in the treatment of HCV. Treatment initially consisted of interferon, the use of which was limited to only those patients with progressive liver disease due to the adverse effects of interferon regimens. The use of DAAs, however, has increased the pool of patients eligible for therapy. Current treatment with DAAs is not only highly effective but also safe and tolerable. (35) The current SVR in patients with HCV is over 90% regardless of a patient's HCV genotype. (27) Besides achieving SVR in infected individuals, DAAs can also have a great impact in decreasing HCV transmission. Similar to the success of the treatment-as-prevention strategy in HIV infection where antiretroviral therapy reduced the rate of transmission by 96%, scaling up HCV treatment with DAAs among IVDU has been predicted to lower HCV prevalence. (36, 37) Using a mathematical model, Martin et al. (37) have shown that by increasing the HCV treatment rate by 15, 40, and 76 treatments per 1,000 IVDU per year, we can achieve a 50% prevalence reduction in 15 years in Edinburg, United Kingdom; Melbourne, Australia; and Vancouver, Canada, respectively. As the chronic HCV prevalence increases, a greater treatment scale-up is required to achieve 50% prevalence reduction in 15 years.
Synergy with Other Interventions
Synergy with other interventions refers to a public health initiative's ability to use existing infrastructures to implement its agenda. SNPs originally designed for HIV prevention also lower the incidence of HCV. (28) Integrating HCV and HIV counseling and testing at community outreach programs increases the rate of disease screening significantly compared to offering them separately. (38) The emergency room has been proposed as another possible point for screening as the addition of HCV screening did not increase the emergency room length of stay when there were other laboratory tests involved. (39) The use of an electronic HCV screening reminder in existing electronic health medical records has been shown to increase the number of screening tests by 145% in a large academic health care system. (17) Family physicians and nurse practitioners were able to achieve similar SVR rates to those of a specialist with DAAs after 3 hours of guideline-based training. (40) Both the Hepatitis C Therapeutic Registry and Research Network and the Translational Research in Oncology Network reported equivalent SVR rates among community clinics, hospitals, and clinical trials, suggesting that HCV treatment can be delivered effectively using existing community clinics and personnel. ( 
40-42)
Field-Proven Strategies
No health system has successfully eliminated HCV, but there are a number of organized efforts that achieve initial success by establishing a national committee, having strong government support, and using a universal health care system. For instance, Georgia became the first nation to launch a national campaign to eliminate HCV in 2015. From January 2015 to December 2016, several mass HCV screening programs were conducted in Georgia that targeted high-risk groups (e.g., IVDU, prisoners, patients with HIV) and led to the identification of 50,962 HCV antibody-positive individuals, with 59% of those confirmed to have chronic HCV infection by polymerase chain reaction testing. Through partnership with the pharmaceutical industry, Georgia was able to offer DAA agents free of charge and increase the average monthly number of patients receiving treatment by 300% in 2016. Since the launch of the national campaign, the number of treatment centers has increased from 4 to 27. (43) Another global example is Egypt, which formed the National Committee for Control of Viral Hepatitis and subsequently established more than 54 dedicated centers that manage approximately 800,000 patients with chronic HCV. A national database was also established to monitor HCV elimination progress. Furthermore, the National Committee for Control of Viral Hepatitis was able to negotiate with Gilead Sciences to provide sofobuvir at a reduced price of 300 USD per bottle (compared to 28,000 USD per bottle in the United States). (44, 45) Australia has made progress in eliminating HCV by initiating DAA treatment in 32,400 patients, a 10-fold increase from the previous year and equating to 14% of the total patients with HCV nationally. (46) There were two main factors contributing to this success. First, the Australian government invested 1.6 billion USD to expand HCV treatment access to all affected adults and successfully negotiated lower DAA prices. Second, the medical community was able to increase the proportion of DAA treatment prescribed by a general practitioner from 8% to 31%, thus making treatments more accessible to patients. (47) In the United States, the Veterans Affairs (VA) health care system has had some success against HCV, with 2.9 million patients (53% of the total VA patient population) screened for HCV; of those with HCV viremia, 39,388 patients (23%) have initiated treatment, a percentage that is higher than the national average. High treatment cost continues to be a significant barrier in the VA system and forces providers to prioritize patients for DAAs. (48) HCV elimination in any of these three populations still requires significant expansion of their current operations, but these efforts will certainly present learning opportunities for other entities.
Effective Strategies
A hepatitis C elimination strategy requires effective utilization of all available interventions and coordinated efforts among government, industry, and professional societies. All adults 20 to 69 years of age should receive at least one HCV screening, with a special focus on high-risk populations. (49) (50) (51) Access to DAAs must be increased by negotiations between government and industry so that treatment is available to all patients regardless of ability to pay. Public health infrastructure must be scaled up significantly to provide comprehensive care, including SNP, OST, social support, and mental health service. Community outreach programs must also be scaled up to reach hidden populations, namely patients who are homeless and IVDU. Large health care systems should consider incorporating patient coordinators to increase linkage between testing and care. Hospitals and clinics must aim to provide a safe and nonjudgmental environment to care for stigmatized populations and educate primary care providers in treating hepatitis C effectively. (27) Overall, technical feasibility favors HCV elimination with the lack of a nonhuman host, sensitive diagnostic tests, and potent interventions. Despite the lack of field-proven strategies, current efforts in Egypt, Georgia, and Australia will provide valuable lessons in designing our own initiatives, including establishing a national committee and an HCV surveillance program. Existing infrastructures can be used effectively but still require a significant upgrade to match the scale of the HCV epidemic. The challenge remains to design social policy and clinical guidelines that will address the current gaps in the HCV care cascade.
ECONOMIC CONSIDERATIONS
Any public health initiative must take into account not only technical feasibility but also economic considerations. HCV is a significant economic burden on the U.S. health care system. The cost of HCV is composed of direct costs (e.g., hospital admissions, medications, emergency rooms, doctor visits, blood tests, and rehabilitation center), indirect costs (e.g., patients' lost wages, family members' lost wages, employment, and productivity), and impairment in patient-reported outcomes, such as health-related quality of life. (52) The total economic burden of HCV has been estimated to be around 6.5 billion USD annually, with 1.5 billion USD from HCV extrahepatic manifestations. (4, 6, 53) This economic burden coupled with the high price of DAAs has raised concerns over health care budgets for HCV elimination. As a result, multiple investigators have evaluated the cost effectiveness of both screening and treating HCV.
Cost-Effective Diagnostic Tests
Several studies have demonstrated that universal screening for HCV is cost effective.
(49,50) Coffin et al. (49) evaluated the cost effectiveness of a one-time HCV screening of United States individuals age 20 to 69 years against the current risk-based screening guidelines while assuming treatment strategy and cost based on the 2011 American Association for the Study of Liver Diseases guidelines. (54) The simulation showed that recommending a one-time HCV screening in the general population would be more cost effective than the current risked-based screening. (49, 54) Eckman et al. (50) also concluded that the screening and treatment of any population with a prevalence above 0.84% would be cost effective. A systematic review in 2016 suggested that HCV screening is cost effective in the general population, in the birth cohort of individuals born between 1945 and 1965, and among IVDU. (51) These studies have suggested that recommending a one-time screening for HCV in the general population would be cost effective and enable us to fully grasp the magnitude of our current HCV endemic.
Correctional facilities offer another unique opportunity to screen a high-prevalence HCV population (23.1% to 41.2%) that is institutionalized and more accessible compared to other groups, such as people who are homeless and IVDU.
(2) Using a simulation model, it has been shown that the U.S. health care system will save almost 700 million USD in HCVassociated costs over 30 years if a one-time opt-out HCV screen is implemented in all state prisons for 5 years. (55) According to a report by the Bureau of Justice Statistics, up to 80% of state prisons have HCV screening programs but only 8.6% of those programs were considered broad coverage despite HCV prevalence among inmates being at 17%. (56, 57) More recently, a survey of 58 prisons and jails showed that the majority of HCV testing is either by inmate request or physician order; only five facilities have mandatory testing. (58) 
Cost-Effective Treatment
The treatment of HCV using DAAs has been shown to be cost effective and even cost saving, depending on the cost of drug therapy. (59) In a systematic review, the median drug price threshold below which the treatment with first-generation DAAs and second-generation DAAs became cost effective was 120,100 and 227,200 USD, respectively. (59) The corresponding median drug price threshold below which the treatment with first-generation DAAs and secondgeneration DAAs became cost saving was 11,700 and 70,900 USD, respectively. Despite the high costs of second-generation DAAs, these treatments are cost effective.
Although HCV treatment is cost effective or even cost saving, the up-front costs make universal treatment impractical at the moment. A budget impact study revealed that, depending on the estimate of HCV prevalence, the total treatment cost using sofosbuvir and ledipasvir can range from 136 to 425 billion USD for an HCV prevalence between 1.6 million to 5 million cases, respectively, using whole-sale pricing. (60) As a comparison, the total health care spending of the United States federal government was 3.2 trillion USD in 2016 while allocating approximately 26 billion USD domestically for HIV with 20 billion USD spent directly on HIV health services and medications. (61, 62) 
Intangible Benefits
Besides improving clinical outcomes, such as survival, achieving SVR in those infected will also have intangible benefits, such as improvement of patientrelated outcomes (PROs). (63, 64) The results of recent studies using interferon-and ribavirin-free regimens with DAAs have shown an increase in PRO scores, which represent quality of life, in all four validated questionnaires: the Short Form Health Survey, the Functional Assessment of Chronic Illness TherapyFatigue, the Chronic Liver Disease Questionnaire-HCV Version, and the Work Productivity and Activity Index: Specific Health Problem. (52, 65) This increase in PRO scores was observed in patients with and without cirrhosis. (66) Eliminating hepatitis C by treating those infected or preventing new infections produces savings in monetary value, an increase in productivity, and a reduction in mortality. Early SVR has been associated with a 74% reduction in all-cause mortality. (67) Achieving early SVR also lowered the overall medical cost by 13-fold in the 5-year posttreatment period. (68) These potential savings are especially meaningful because providing value-based care has been the focus of national discussion in recent years due to an escalation in health care spending. Besides the obvious savings in direct cost (e.g., hospitalizations, medications, laboratory tests, and emergency services), eliminating HCV will also produce indirect savings (e.g., gained productivity, reducing social assistance spending) and other PROs, such as with respect to emotional health and cognitive impairment. Additionally, many cost-effective analyses have not taken into account the cost of preventing extrahepatic manifestations of HCV, which represents additional savings from HCV elimination.
SOCIAL AND POLITICAL ATTENTION
Social and political support are perhaps the most challenging aspects given the stigma associated with HCV patient populations. The availability of DAAs is encouraging, but these interventions will only help patients with access to medical care while excluding the marginalized populations, namely the incarcerated, IVDU, and patients who are homeless. The HCV prevalence in these high-risk populations has been estimated to be at least 22%, while composing 42% of total cases in the United States.
(2) Our current lack of political support and pervasive social stigma continue to pose significant barriers for interventions to reach the most vulnerable populations affected by HCV.
Social Support
Social stigma also impedes efforts to eliminate HCV by hindering public support for meaningful policy changes. Despite evidence that drug addiction is a chronic relapsing disease, drug use is almost always viewed as personal irresponsibility without accounting for underlying problems that led to drug addiction. (69, 70) As a result, patients with HCV often face stigmatization in the health care and social settings. (70, 71) This stigma explains the recent opposition to safe injection sites initiatives by Boston city councilors despite evidence that these sites lower the risk of transmitting diseases by promoting safer injection techniques. (72, 73) Safe injection sites is a pragmatic step to contain health care cost and does not equate to endorsing drug use. Breaking this social stigma will require a coordinated effort from public health organizations, professional societies, and medical schools to educate both the public and providers. (43) Funding for HCV research has suffered from lack of promotion and public awareness. Despite HCV and HIV sharing similarities, HIV has acquired the status of being an "exceptional disease" due to successful promotions and has attracted much more funding. (74) According to CDC data in 2014, HIV/AIDS prevalence is approximately 1.1 million with 8,300 deaths, while numbers for HCV indicate a prevalence of 3.9 million with 19,566 deaths. (75) (76) (77) Data reported by the NIH showed that HCV received 111 million USD in funding while HIV/AIDS received 3 billion USD in funding despite the greater prevalence and mortality of HCV (Table 3) . (77) This discrepancy is partly because HIV mostly affects men who have sex with men who can advocate for themselves, whereas HCV mostly affects IVDU who more likely end up in prisons and are unable to rally public support. (78, 79) Therefore, health care providers and social activists must intensify efforts to advocate for HCV elimination.
Political Support
Current law enforcement practices contribute to IVDU reluctance to disclose their drug use and access necessary preventive care. Strict regulations regarding the sale and distribution of clean needles and syringes from pharmacies continue to undermine public efforts to limit blood-borne diseases. (24) These policy changes must be the focus of any legislators and social advocates who support HCV elimination.
Technical Consensus
In contrast to the challenges posed by the criminal justice system, HCV elimination in the United States has gained the support of professional societies. In 2016, the National Academy of Science, Engineering, and Medicine published a national strategy report that identifies HCV and hepatitis B virus as a significant threat to public health that must be addressed. (79) This report explores the feasibility and barriers that must be overcome to eliminate HCV in the United States and has been sponsored by the Association for the Study of Liver Diseases. (79, 80) Similarly, the WHO published an advocacy brief highlighting the burden, urgency, and estimated cost for a hepatitis B and C elimination strategy in low-and middle-income countries. (81) Nevertheless, we have seen encouraging signs in the past decade. The California senate will vote on legislation allowing supervised drug injection sites, and if passed, the legislation will make California the first state to have such sites. (82) Additionally, the CDC has designated May as Hepatitis C Awareness Month to encourage screening of high-risk populations. Correctional facilities are an ideal setting to screen and educate a high-HCV prevalence population, but this opportunity has been largely neglected; any intervention program in this population will be very impactful. Health care providers and social activists must continue to be proactive and advocate for necessary legislative changes, such as relaxing harsh penalties for minor drug offenses and eliminating restrictions on syringe and needle sales in pharmacies. 2.7 million-3.9 million 1.1 million Mortality (77) 19,566 8,300 NIH research funding (77) $107 million $3 billion
Abbreviation: NIH, National Institutes of Health.
Conclusions
HCV elimination is technically feasible in the United States but continues to face multiple challenges and will require the collaboration of health care systems, pharmaceutical companies, social advocates, and policy makers. The crucial first step is to establish an HCV elimination national committee to coordinate efforts from different sectors and levels of government. This national committee can advocate for the allocation of resources needed for a surveillance database, SNPs, social safety networks, vaccine research, and initiatives to break down social stigma. Political leaders must spearhead meaningful policy changes. Government and pharmaceutical companies must start negotiations to lower drug prices for improved DAA access. Research continues to provide new insights on how to use our current technology cost effectively for HCV elimination. Multiple cost-effective analyses support general population HCV screening in addition to high-risk populations. Treatment with DAAs has been shown to be very cost effective even at the current price point. Vaccine development is making progress with three vaccines currently in clinical trials.
Several countries have taken the first steps to address HCV infection through the creation of nationwide treatment centers and available treatment. Domestically, the United States VA health system has had early success in screening and treating its patient population at a higher rate than the general population. HCV elimination is an ambitious goal for any health care system; however, with technological advances and existing infrastructure, the United States has the potential to become the first nation to eliminate HCV if it can secure sustained public support and political commitment.
